High-concentration allicin composition injection and preparation process thereof

By using mannitol and polyethylene glycol to form a stable intramolecular cohesive system, the solubility and stability issues of allicin injection were resolved, thus improving the safety and stability of high-concentration allicin injection and avoiding allergic reactions.

CN116549384BActive Publication Date: 2026-11-10GUANGZHOU ZESHENG PHARM TECH CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202310716336.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-06-15
Publication Date
2026-11-10
Estimated Expiration
2043-06-15

AI Technical Summary

Technical Problem

The use of polysorbate-80 and ethanol in existing allicin injections leads to allergic reactions, poor solubility, and unsatisfactory stability. There is an urgent need to develop an injection that does not contain these ingredients to improve safety and stability.

Method used

Mannitol and polyethylene glycol are used as excipients and mixed with allicin to form a stable intramolecular cohesive system. High-concentration allicin injection is prepared by activated carbon treatment and multi-stage filtration, avoiding the use of polysorbate-80 and ethanol.

Benefits of technology

It improves the clarity and content of active ingredients in the injection solution, reduces irritation, ensures product stability at room temperature for 24 months, reduces storage costs, and enhances safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116549384B_ABST
    Figure CN116549384B_ABST
Patent Text Reader

Abstract

The present application relates to the technical field of traditional Chinese medicine composition production process, in particular to a high-concentration allicin composition injection and a preparation process thereof.The injection raw materials include: 1.0-1.5 parts of allicin, 5-8 parts of mannitol, 40-60 parts of polyethylene glycol, and water for injection to make up 100 parts; and the pH value is 3.0-5.5.The preparation process is as follows: mixing allicin and polyethylene glycol to obtain a first drug mixture; dissolving mannitol in water to obtain a mannitol solution; mixing the drug mixture and the mannitol solution to obtain a second drug mixture; adjusting the pH value of the second drug mixture and adding water to obtain the original injection; and using activated carbon to treat and filtering to obtain the allicin injection.Mannitol, polyethylene glycol and allicin form a stable intramolecular aggregation system in the solution, the polysorbate 80 and ethanol in the original prescription are removed, the safety of the product is improved, the stability of the product is also improved, and the product has an ideal application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of traditional Chinese medicine composition production technology, specifically to a high-concentration allicin composition injection and its preparation process. Background Technology

[0002] Allicin is hailed as a natural broad-spectrum antibiotic. First discovered by Pasteur in the 19th century, garlic possesses antibacterial activity. Subsequent research has demonstrated that allicin exhibits unique pharmacological activity, readily penetrating phospholipid membranes to enter cells and interacting with certain entrapment compounds to achieve its pharmacological effects. In addition, it also possesses pharmacological effects such as anti-tumor activity, cholesterol reduction, anti-platelet aggregation, liver protection, prevention of cardiovascular disease, blood pressure reduction, and antioxidant properties. In recent years, pharmacological research on allicin has become increasingly extensive and in-depth both domestically and internationally, and various allicin preparations have been successively applied clinically. Allicin injection is an anti-infective drug suitable for deep fungal and bacterial infections, used to prevent and treat acute and chronic bacillary dysentery and enteritis, pertussis, fungal infections of the lungs and digestive tract, candidiasis, cryptococcal meningitis, and tuberculosis.

[0003] Currently, the excipient composition of commercially available allicin injection solutions generally includes: ① polysorbate 80, 2-hydroxypropyl-β-cyclodextrin, and ethanol; ② propylene glycol, polysorbate-80, L-glutamic acid, and ethanol; ③ polysorbate-80, sorbitol, and ethanol, etc. Patients often experience allergic or irritant reactions when receiving a diluted solution of allicin injection with glucose or sodium chloride injection. These adverse reactions are mainly caused by the addition of a certain amount of polysorbate-80 and ethanol to the injection solution. Allicin has poor water solubility, and the stability of allicin injection solutions is not ideal. Without the addition of polysorbate-80 and ethanol, the allicin injection solution would suffer from defects in water solubility and stability. Even with the use of polysorbate-80 and ethanol, multi-stage filtration is required to ensure solution clarity, but multi-stage filtration leads to a decrease in the content of the active ingredient in the injection solution. There is an urgent need to develop an allicin injection that does not contain irritating ingredients such as polysorbate-80 and ethanol, while ensuring the content of active ingredients and the quality of the finished product to meet market demand. Summary of the Invention

[0004] The present invention aims to provide a preparation process for allicin injection that improves clarity and content of active ingredients, in order to solve the technical problem that allicin injection obtained by existing production processes may lead to adverse reactions.

[0005] To achieve the above objectives, the present invention adopts the following technical solution:

[0006] A process for preparing a high-concentration allicin composition injection includes the following steps:

[0007] S1: Mix allicin and polyethylene glycol to obtain a first drug mixture; dissolve mannitol in water to obtain a mannitol solution; mix the drug mixture and the mannitol solution to obtain a second drug mixture;

[0008] S2: Adjust the pH of the second drug mixture and add water to obtain the original injection solution;

[0009] S3: The original injection solution is treated with activated carbon and then filtered to obtain the activated carbon-treated injection solution.

[0010] S4: The injection solution after activated carbon treatment is then filtered to obtain allicin injection solution.

[0011] This technical solution also provides a high-concentration allicin composition injection, which, by weight, comprises: 1.0 to 1.5 parts allicin, 5 to 8 parts mannitol, 40 to 60 parts polyethylene glycol, and water for injection to make up to 100 parts; and has a pH value of 3.0 to 5.5.

[0012] Furthermore, in S1, the mass ratio of allicin, mannitol, and polyethylene glycol is 1.0–1.5:5–8:40–60; the molecular weight of polyethylene glycol is 300–400.

[0013] Furthermore, in S2, the pH of the second drug mixture is adjusted to 3.0–5.5.

[0014] Furthermore, in S3, the activated carbon is for injection and is used at 0.01% in the original injection solution.

[0015] Furthermore, in S3, the original injection solution is treated with activated carbon for 30 minutes, and then decarbonized by filtration with a 5μm titanium filter rod.

[0016] Furthermore, in S4, the filtration process involves sequentially filtering the activated carbon-treated injection solution using 0.45μm and 0.22μm microporous filter elements.

[0017] Furthermore, the pH value of the allicin injection solution is 4.5–5.0.

[0018] Furthermore, the polyethylene glycol is polyethylene glycol 300 or polyethylene glycol 400.

[0019] Furthermore, the allicin injection solution is available in 2ml vials.

[0020] In summary, the beneficial effects of this technical solution are as follows:

[0021] (1) Mannitol, polyethylene glycol and allicin in the prescription form a stable molecular intrapolymer system in the solution, which plays a good role in solubilization and solves the problem that allicin is easy to precipitate solids during preparation or storage. In addition, the stable molecular intrapolymer system greatly improves the stability of the product. The product remains stable after being stored at room temperature for 24 months, which solves the problem of harsh storage conditions for the product and reduces storage costs.

[0022] (2) This technical solution removes polysorbate 80 and ethanol from the original formula, which greatly reduces the irritation of the product and improves the safety of the product.

[0023] (3) Using water as a solvent (without adding ethanol), allicin has poor stability and poor solubility. This technical solution adds substances such as polyethylene glycol and mannitol to overcome the problems caused by using water as a solvent. Attached Figure Description

[0024] Figure 1 This is the product appearance of Embodiment 1 of the present invention.

[0025] Figure 2 The product appearance is shown in Comparative Example 1 of this invention.

[0026] Figure 3 The product appearance of Comparative Example 3 of this invention is shown. Detailed Implementation

[0027] The present invention will be further described in detail below with reference to embodiments, but the embodiments of the present invention are not limited thereto. Unless otherwise specified, the technical means used in the following embodiments and experimental examples are conventional means well known to those skilled in the art, and the materials, reagents, etc. used are all commercially available. Unless otherwise specified, the technical means used in the following embodiments are conventional means well known to those skilled in the art.

[0028] Example 1

[0029] (1) Allicin Composition Injection Formulation:

[0030] The raw material composition of the allicin composition injection solution, by weight, is as follows: 1.0–1.5 parts allicin, 5–8 parts mannitol, 40–60 parts polyethylene glycol, and water for injection to make up to 100 parts. The pH value of the allicin composition injection solution is 3.0–5.5 (preferably 4.5–5.0). Allicin is diallyl thiosulfinate, and its purity must be above 98.0% in this formulation. The molecular weight of polyethylene glycol is 300–400 (i.e., polyethylene glycol 300 and polyethylene glycol 400 can be used, conforming to the standards of the Chinese Pharmacopoeia, Part IV, for polyethylene glycol 300 (for injection) and polyethylene glycol 400 (for injection)). Mannitol conforms to the standards of the Chinese Pharmacopoeia, Part II, for mannitol.

[0031] (2) The preparation process includes the following steps:

[0032] ① Weigh out the prescribed amounts of allicin and polyethylene glycol, place them in a mixing tank, and stir until homogeneous; take the prescribed amounts of mannitol and 80% of the total volume of water for injection, dissolve them, stir until homogeneous, add them to the above-mentioned drug solution, and stir until homogeneous.

[0033] ② Adjust the pH value to between 3.0 and 5.5 (preferably 4.5 to 5.0) with 10% hydrochloric acid solution, add water for injection to the amount of water specified in the formula, and stir well.

[0034] ③ Weigh 0.01% (g / ml) of the solution obtained in ② (i.e., the total amount prepared) of activated carbon for injection (implementing standard: activated carbon for injection, Part IV of Chinese Pharmacopoeia)), add it to the solution, stir and adsorb at room temperature for 30 minutes, and filter with a 5μm titanium filter rod to remove carbon.

[0035] ④ Filtration: Filter the solution using 0.45μm and 0.22μm microporous filter cartridges respectively.

[0036] ⑤ Filling; fill into 2ml brown ampoules, seal by melting, and then perform routine sterilization (i.e., terminal sterilization). Using this technical solution, the allicin concentration of the allicin composition injection can reach 30mg / 2ml.

[0037] ⑥ Light inspection.

[0038] ⑦ After passing inspection, package, inspect, and put into storage.

[0039] To further illustrate the effect, this embodiment is carried out according to the following description:

[0040] Formula: 1.5 parts allicin, 7 parts mannitol, 40 parts polyethylene glycol (PEG 400), and water for injection to make up to 100 parts. In step ②, adjust the pH of the injection solution to approximately 4.5. See the image for product status (unsterilized). Figure 1 The product turns slightly yellow after sterilization.

[0041] Example 2

[0042] This embodiment is basically the same as Embodiment 1, except that the pH value of the injection is adjusted to 5.0 and polyethylene glycol 300 is used.

[0043] Example 3

[0044] This embodiment is basically the same as Embodiment 1, except that the pH value of the injection is adjusted to 3.0.

[0045] Example 4

[0046] This embodiment is basically the same as Embodiment 1, except that the pH value of the injection is adjusted to 5.5.

[0047] Example 5

[0048] This embodiment is basically the same as Embodiment 1, except that the formulation of the injection solution is 1.5 parts allicin, 5 parts mannitol, 60 parts polyethylene glycol, and water for injection to make up to 100 parts.

[0049] Example 6

[0050] This embodiment is basically the same as Embodiment 1, except that the formulation of the injection solution is 1.5 parts allicin, 8 parts mannitol, 60 parts polyethylene glycol, and water for injection to make up to 100 parts.

[0051] Example 7

[0052] This embodiment is basically the same as Embodiment 1, except that the formulation of the injection solution is 1.0 part allicin, 5 parts mannitol, 40 parts polyethylene glycol, and water for injection to make up to 100 parts.

[0053] Example 8

[0054] This embodiment is basically the same as Embodiment 1, except that the formulation of the injection solution is 1.0 part allicin, 5 parts mannitol, 60 parts polyethylene glycol, and water for injection to make up to 100 parts.

[0055] Example 9

[0056] This embodiment is basically the same as Embodiment 1, except that the formulation of the injection solution is 1.0 part allicin, 8 parts mannitol, 60 parts polyethylene glycol, and water for injection to make up to 100 parts.

[0057] Comparative Example 1

[0058] This comparative example is basically the same as Example 1, except that the pH value of the injection is adjusted to 6.0. See the image for product status (unsterilized). Figure 2 The product turns slightly yellow after sterilization.

[0059] Comparative Example 2

[0060] This comparative example is basically the same as Example 1, except that the pH value of the injection is adjusted to 2.5.

[0061] Comparative Example 3

[0062] This comparative example is basically the same as Example 1, except that the formulation of the injection solution is 1.5 parts allicin, 40 parts polyethylene glycol, and water for injection to make up to 100 parts, without the addition of mannitol. The preparation process is the same as in Example 1, except for step ①. The specific steps that have changed are: ① Weigh the prescribed amounts of allicin and polyethylene glycol, place them in a mixing tank, stir evenly, then add 80% of the total volume of water for injection, and stir evenly. See product status image below. Figure 3 The product turns slightly yellow after sterilization.

[0063] Comparative Example 4

[0064] This comparative example is basically the same as Example 1, except that the formulation of the injection solution is 1.5 parts allicin, 7 parts mannitol, and water for injection to make up to 100 parts, and polyethylene glycol is not added. The preparation process is the same as in Example 1, except for step ①. The specific steps that have changed are: ① Take the prescribed amount of mannitol and 80% of the total volume of water for injection, dissolve them, stir evenly, then add the prescribed amount of allicin and stir evenly.

[0065] Comparative Example 5

[0066] This comparative example is basically the same as Example 1, except that mannitol is replaced in equal amounts with its isomer sorbitol.

[0067] Comparative Example 6

[0068] This comparative example is basically the same as Example 1, except that mannitol is replaced with xylitol in equal amounts.

[0069] Comparative Example 7

[0070] This comparative example is basically the same as Example 1, except that mannitol is replaced with an equal amount of L-glutamic acid.

[0071] Comparative Example 8

[0072] This comparative example is basically the same as Example 1, except that mannitol is replaced with an equal amount of 2-hydroxypropyl-β-cyclodextrin.

[0073] Comparative Example 9

[0074] This comparative example is basically the same as Example 1, except that mannitol is replaced with maltose in equal amounts.

[0075] Comparative Example 10

[0076] This comparative example is basically the same as Example 1, except that the formulation of the injection solution is 1.5 parts allicin, 7 parts mannitol, 40 parts propylene glycol, and water for injection to make up to 100 parts. In this comparative example, propylene glycol is used instead of polyethylene glycol 400 in the formulation, and the preparation process also uses propylene glycol instead of polyethylene glycol 400 in the corresponding process steps.

[0077] Comparative Example 11

[0078] This comparative example is basically the same as Example 1, except that the formulation of the injection solution is 1.5 parts allicin, 7 parts mannitol, 40 parts polysorbate 80, and water for injection to make up to 100 parts. In this comparative example, polysorbate 80 is used instead of polyethylene glycol 400 in the formulation, and the preparation process also uses polysorbate 80 instead of polyethylene glycol 400 in the corresponding process steps.

[0079] Comparative Example 12

[0080] This comparative example is basically the same as Example 1, except that the formulation of the injection solution is 1.5 parts allicin, 7 parts mannitol, 40 parts polyethylene glycol 600, and water for injection to make up to 100 parts. In this comparative example, polyethylene glycol 600 is used instead of polyethylene glycol 400 in the formulation, and the preparation process also uses polyethylene glycol 600 instead of polyethylene glycol 400 in the corresponding process steps.

[0081] Comparative Example 13

[0082] This comparative example is basically the same as Example 1, except that the formulation of the injection solution is 1.5 parts allicin, 7 parts mannitol, 40 parts glycerol, and water for injection to make up to 100 parts. In this comparative example, glycerol is used instead of polyethylene glycol 400 in the formulation, and the preparation process also uses glycerol instead of polyethylene glycol 400 in the corresponding process steps.

[0083] Comparative Example 14

[0084] This comparative example is basically the same as Example 1, except that the preparation process has been adjusted. The specific adjustment steps are as follows, and the rest is the same as Example 1: ① Take the prescribed amount of allicin, polyethylene glycol, mannitol and 80% of the total volume of water for injection, place them in a mixing tank, and stir evenly.

[0085] Comparative Example 15

[0086] This comparative example is basically the same as Example 1, except that the preparation process has been adjusted. The specific adjustment steps are as follows, and the rest is the same as Example 1: ① Weigh the prescribed amount of mannitol and 80% of the total volume of water for injection, place them in a mixing tank, dissolve them, stir evenly, and then add the prescribed amounts of allicin and polyethylene glycol, and stir evenly.

[0087] Experimental Example

[0088] (I) Quality Inspection of Allicin Injection

[0089] The quality of allicin injection was assessed, with the following indicators included: pH value, insoluble microparticles (General Rule 0903), appearance, and content. The appearance, pH value, and content were tested according to the national drug standard for allicin injection (Standard No.: YBH19642006).

[0090] Insoluble particulate matter: Refer to General Rule 0903, as follows:

[0091] Inspection method

[0092] (1) For intravenous injection solutions or concentrated solutions for injection with a labeled volume of 25 ml or more, unless otherwise specified, take at least 4 test samples and determine them according to the following method: Wash the outer wall of the container with water, carefully turn it 20 times on a clean workbench to mix the solution evenly, immediately and carefully open the container, and use an appropriate method to draw or measure 25 ml of the test solution and slowly pour it into the pretreated filter (filter membrane diameter 25 mm) along the inner wall of the filter. Let it stand for 1 minute, and slowly filter until the filter membrane is nearly dry. Then, use 25 ml of water for particle testing, slowly pour it along the inner wall of the filter, wash and filter until the filter membrane is nearly dry. Then, use flat-tipped forceps to transfer the filter membrane onto a petri dish (if necessary, a very thin layer of glycerin can be applied to make the filter membrane flat), slightly open the lid to allow the filter membrane to dry appropriately, close the petri dish, and place it on the microscope stage. Adjust the incident light, magnify 100x for microscopic measurement, adjust the microscope until the filter membrane grid is clear, move the coordinate axis, and measure the number of particles with a longest diameter greater than 10 μm and 25 μm on the effective filtration area, respectively. Calculate the average value of the measurement results for the three test samples.

[0093] (2) Unless otherwise specified, for intravenous injection solutions or concentrated solutions for injection with a labeled volume of 25 ml or less, take at least 4 test samples, wash the outer wall of the container with water, carefully turn it over 20 times on a clean workbench to mix it evenly, immediately and carefully open the container, and use an appropriate method to directly extract all the solution in each container, and slowly inject it into the pretreated filter (filter membrane diameter 13 mm) along the inner wall of the filter, and determine it in the same way as (1) above.

[0094] Result determination

[0095] (1) Unless otherwise specified, intravenous injection solutions with a labeled volume of 100ml or more shall contain no more than 12 particles of 10μm or larger per ml and no more than 2 particles of 25μm or larger per ml.

[0096] (2) Unless otherwise specified, for intravenous injection solutions, sterile powders for intravenous injection, concentrated solutions for injection and sterile raw materials for injection with a labeled volume of less than 100 ml, the number of particles of 10 μm and above in each test sample container shall not exceed 3,000, and the number of particles of 25 μm and above shall not exceed 300.

[0097] (II) Stability Assessment

[0098] The stability of the injection was investigated in accordance with the Chinese Pharmacopoeia, Part IV (9001 Guidelines for Stability Testing of Raw Materials and Preparations).

[0099] The accelerated testing is conducted to investigate the stability of pharmaceutical formulations by accelerating their chemical or physical changes, providing necessary data for formulation design, process improvement, quality research, packaging improvement, transportation, and storage. The test sample is placed at 40℃±2℃ and 75%±5% relative humidity for 6 months. Samples are taken and tested at three time points (e.g., 0, 3, and 6 months) during the testing process.

[0100] The test results are shown in Table 1. The experimental results show that the formula and manufacturing process of this scheme can produce a slightly yellow and transparent allicin injection solution. The insoluble particle test of the injection solution meets the requirements, and the allicin content also meets the requirements. The pH values ​​of Comparative Examples 1 and 2 are not within the pH range required by this scheme, which leads to slight turbidity in the solution. Further insoluble particle testing revealed an increase in the number of various types of insoluble particles. Although the products of Comparative Examples 1 and 2 meet the standard requirements, their quality is not ideal. Comparative Example 3 did not contain mannitol, and Comparative Example 4 did not contain polyethylene glycol; both showed a significant increase in turbidity. This indicates that when using water as the sole solvent (without ethanol), polyethylene glycol and mannitol need to be used in combination to ensure sufficient dissolution of allicin and to guarantee the clarity of the product and that all properties meet the requirements. Comparative Examples 5, 6, 7, 8, and 9 demonstrate the inventor's process of selecting suitable solubilizing agents. They found that, except for mannitol, other substances used in combination with polyethylene glycol could not guarantee the solubility of allicin and the clarity of the product in an aqueous environment. Comparative Examples 10, 11, 12, and 13 also demonstrate the inventor's process of selecting suitable solubilizing agents. They found that, except for polyethylene glycol (300 and 400), other substances used in combination with mannitol could not guarantee the solubility of allicin and the clarity of the product in an aqueous environment. Comparative Examples 14 and 15 demonstrate the inventor's exploration of the product preparation process. Initially, the inventor mixed allicin, polyethylene glycol, mannitol, and some water in a single step, finding that the clarity of the resulting product was far from ideal. Later, the inventor tried dissolving mannitol first, then adding the prescribed amounts of allicin and polyethylene glycol separately, but the product clarity problem remained unresolved. Through extensive research, the inventors discovered that to maximize product clarity, allicin and polyethylene glycol need to be mixed, mannitol dissolved, and then the two components mixed together. Based on this observation, the inventors analyzed the underlying principle: allicin first needs to mix and contact with polyethylene glycol to form a preliminary intramolecular cohesive system. This preliminary system then combines with mannitol to form a stable intramolecular cohesive system, thereby improving the solubility. Mixing allicin, polyethylene glycol, and mannitol simultaneously makes it difficult to form this stable intramolecular cohesive system. Replacing the solubilizing agents polyethylene glycol and mannitol with other pharmaceutical excipients also hinders the formation of this stable intramolecular cohesive system, making it impossible to guarantee the solubility of allicin and product clarity when using water as a solvent.

[0101] Table 1: Quality test results of the injection solutions in the examples and comparative examples (the content of insoluble microparticles and allicin is the average of three replicates; "uncountable" and " / " indicate that the product is too turbid and not suitable for this test item, and the test item cannot be performed).

[0102]

[0103] Stability tests were conducted on the products obtained from the qualified examples or comparative examples in Table 1, and the test results are shown in Table 2. The products obtained in Examples 1-4 exhibited excellent stability, with only a minimal decrease in allicin content during accelerated testing. However, the pH values ​​used in Comparative Examples 1 and 2 differed from those in the examples, resulting not only in slight turbidity but also in a significant decrease in the amount of active ingredients during accelerated testing.

[0104] Table 2: Results of accelerated testing (n=3)

[0105]

[0106] The above descriptions are merely embodiments of the present invention, and common knowledge such as specific technical solutions and / or characteristics are not described in detail here. It should be noted that those skilled in the art can make various modifications and improvements without departing from the technical solutions of the present invention, and these should also be considered within the scope of protection of the present invention. These modifications and improvements will not affect the effectiveness of the implementation of the present invention or the practicality of the patent. The scope of protection claimed in this application should be determined by the content of its claims, and the specific embodiments described in the specification can be used to interpret the content of the claims.

Claims

1. A preparation process for a high-concentration allicin composition injection, characterized in that, Includes the following steps: S1: Allicin and polyethylene glycol are mixed to obtain a first drug mixture; mannitol is dissolved in water to obtain a mannitol solution; The first drug mixture is mixed with a mannitol solution to obtain a second drug mixture; S2: Adjust the pH of the second drug mixture and add water to obtain the original injection solution; S3: The original injection solution is treated with activated carbon and then filtered to obtain the activated carbon-treated injection solution. S4: The injection solution after activated carbon treatment is then filtered to obtain allicin injection solution.

2. The preparation process of a high-concentration allicin composition injection according to claim 1, characterized in that, In S1, the mass ratio of allicin, mannitol and polyethylene glycol is 1.0~1.5:5~8:40~60; the molecular weight of polyethylene glycol is 300~400.

3. The preparation process of a high-concentration allicin composition injection according to claim 2, characterized in that, In S2, the pH of the second drug mixture is adjusted to 3.0~5.

5.

4. The preparation process of a high-concentration allicin composition injection solution according to claim 3, characterized in that, In S3, the activated carbon is for injection, and the amount used in the original injection solution is 0.01g / 100mL.

5. The preparation process of a high-concentration allicin composition injection according to claim 4, characterized in that, In S3, the original injection solution was treated with activated carbon for 30 minutes, and then decarbonized by filtration with a 5μm titanium filter rod.

6. The preparation process of a high-concentration allicin composition injection solution according to claim 5, characterized in that, In S4, the filtration process involves sequentially filtering the activated carbon-treated injection solution using 0.45μm and 0.22μm microporous filter cartridges.

7. A high-concentration allicin composition injection, characterized in that, By weight, its raw materials include: 1.0-1.5 parts allicin, 5-8 parts mannitol, 40-60 parts polyethylene glycol, and water for injection to make up to 100 parts; and the pH value is 3.0-5.

5. It is prepared by the following method: S1: Mix allicin and polyethylene glycol to obtain a first drug mixture; dissolve mannitol in water to obtain a mannitol solution; mix the first drug mixture and the mannitol solution to obtain a second drug mixture; S2: Adjust the pH of the second drug mixture and add water to obtain the original injection solution; S3: The original injection solution is treated with activated carbon and then filtered to obtain the activated carbon-treated injection solution. S4: The injection solution after activated carbon treatment is then filtered to obtain allicin injection solution.

8. The high-concentration allicin composition injection solution according to claim 7, characterized in that, Its pH value is 4.5~5.

0.

9. The high-concentration allicin composition injection solution according to claim 8, characterized in that, The polyethylene glycol is either polyethylene glycol 300 or polyethylene glycol 400.

10. The high-concentration allicin composition injection according to claim 9, characterized in that, Its specification is 2ml / bottle.

Citation Information

Patent Citations

  • Garlicin concentrated, solution for supply intravenous after composite solvent dilution

    CN1561976A

  • A composition for treating vegetative dystonine syndrome and pharmaceutical preparation and application thereof

    WO2008148303A1